Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials

Oritavancin is a lipoglycopeptide antibiotic with activity against Gram-positive bacteria. Here we describe oritavancin population pharmacokinetics and the impact of patient-specific covariates on drug exposure variability. Concentration-time data were analyzed from two phase 3 clinical trials, SOLO...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Rubino, C. M., Bhavnani, S. M., Moeck, G., Bellibas, S. E., Ambrose, P. G.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2015
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4432154/
https://ncbi.nlm.nih.gov/pubmed/25824211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00176-15
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky